The last drug hit was Sertindole which exhibits antiproliferative activities in breast cancer with a potential application for the treatment of breast-to-brain metastases [66] and by inhibiting the STAT3 signaling pathway in human gastric cancer cells [67]. Here, STAT3 is linked to breast cancer.